Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132535 | 0.89 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5131492 | 0.88 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL5126037 | 0.87 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL5803304 | 0.87 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5131471 | 0.87 | TRPV1 (0.76) | TRPV1 | |
| SCHEMBL5802138 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5782291 | 0.86 | TRPV1 (0.75) | TRPV1 | |
| SCHEMBL5800730 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL27686417 | 0.85 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL5131486 | 0.83 | TRPV1 (0.80) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | claimed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | claimed |
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1622884-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | AstraZeneca AB (SE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096784-A1 | NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223868-A1 | Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) | AVPR1A, AVPR2, TRPV1 | TRPV1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.